U.S FDA Staff Reviewers Raise Concerns Of Risk Of Low Blood Sugar In Patients Treated With Novo Nordisk's Weekly Insulin
Portfolio Pulse from Benzinga Newsdesk
U.S. FDA staff reviewers have raised concerns about the risk of low blood sugar in patients treated with Novo Nordisk's weekly insulin, according to documents cited by Reuters.
May 22, 2024 | 1:20 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
FDA staff reviewers have raised concerns about the risk of low blood sugar in patients treated with Novo Nordisk's weekly insulin. This could lead to regulatory scrutiny and potential delays in approval or additional requirements for the product.
The FDA's concerns about low blood sugar risk could lead to increased regulatory scrutiny, potential delays in product approval, or additional requirements for Novo Nordisk's weekly insulin. This is likely to negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100